BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 21210063)

  • 1. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
    Webb MI; Walsby CJ
    Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
    Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
    Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.
    Webb MI; Walsby CJ
    Dalton Trans; 2015 Oct; 44(40):17482-93. PubMed ID: 26174110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
    Mu C; Chang SW; Prosser KE; Leung AW; Santacruz S; Jang T; Thompson JR; Yapp DT; Warren JJ; Bally MB; Beischlag TV; Walsby CJ
    Inorg Chem; 2016 Jan; 55(1):177-90. PubMed ID: 26652771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
    Webb MI; Walsby CJ
    Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 15. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
    Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
    J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.
    Brindell M; Stawoska I; Supel J; Skoczowski A; Stochel G; van Eldik R
    J Biol Inorg Chem; 2008 Aug; 13(6):909-18. PubMed ID: 18438690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed-valent metals bridged by a radical ligand: fact or fiction based on structure-oxidation state correlations.
    Sarkar B; Patra S; Fiedler J; Sunoj RB; Janardanan D; Lahiri GK; Kaim W
    J Am Chem Soc; 2008 Mar; 130(11):3532-42. PubMed ID: 18290644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in ruthenium anticancer drugs.
    Levina A; Mitra A; Lay PA
    Metallomics; 2009 Nov; 1(6):458-70. PubMed ID: 21305154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
    Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
    Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
    Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
    J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.